QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.104.010579v1 67/6/1852    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okuda, T. Articles by Howell, S. B. Search for Related Content PubMed PubMed Citation Articles by Okuda, T. Articles by Howell, S. B.

Suppression of hREV1 Expression Reduces the Rate at Which Human Ovarian Carcinoma Cells Acquire Resistance to Cisplatin

Department of Medicine and the Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, California

Replicative bypass of many DNA adducts is dependent on the interaction of hREV1 with DNA polymerase and potentially with members of the Y family of DNA polymerases. To examine the role of hREV1 in the development of cisplatin (DDP) resistance, a subline (2008-shREV1-3.3) of the ovarian carcinoma cell line 2008 was isolated in which stable expression of a short hairpin RNA suppressed hREV1 expression to 20% and reduced hREV1 protein level to 43% of that found in the parental cells. The 2008-shREV1-3.3 cells were 1.5-fold more sensitive to the cytotoxic effect of DDP but less sensitive to the mutagenic effect of DDP as evidenced by a 2.6- or 2.7-fold reduction in the ability to induce clones highly resistant to 6-thioguanine or DDP itself, respectively, in the surviving population. Reduction of hREV1 did not alter the initial rate of DDP adduct removal from DNA but did impair both spontaneous and DDP-induced extra-chromosomal homologous recombination, as measured by the recombination-sensitive reporter vector pBHRF. DDP induced an increase in hREV1 protein level. DDP resistance at the population level evolved 2.8-fold more slowly in the 2008-shREV1-3.3 cells than in the parental cells during repeated cycles of drug exposure. The results indicate that hREV1 functions to enhance both cell survival and the generation of drug-resistant variants in the surviving population. DDP up-regulates hREV1, suggesting that it may enhance its own mutagenicity. Most importantly, hREV1 controls the rate of emergence of resistance to DDP at the population level. Thus, hREV1 is an important contributor to DDP-induced genomic instability and the subsequent emergence of resistance.

Received for publication December 22, 2004.

Accepted for publication March 8, 2005.

Address correspondence to: Stephen B. Howell, Department of Medicine 0058, University of California, San Diego, La Jolla, CA. E-mail: showell{at}ucsd.edu

This article has been cited by other articles:

				L. S. Waters, B. K. Minesinger, M. E. Wiltrout, S. D'Souza, R. V. Woodruff, and G. C. Walker Eukaryotic Translesion Polymerases and Their Roles and Regulation in DNA Damage Tolerance Microbiol. Mol. Biol. Rev., March 1, 2009; 73(1): 134 - 154. [Abstract] [Full Text] [PDF]

				J. A. Brown, S. A. Newmister, K. A. Fiala, and Z. Suo Mechanism of double-base lesion bypass catalyzed by a Y-family DNA polymerase Nucleic Acids Res., July 1, 2008; 36(12): 3867 - 3878. [Abstract] [Full Text] [PDF]

				X. Lin and S. B. Howell DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance Mol. Cancer Ther., May 1, 2006; 5(5): 1239 - 1247. [Abstract] [Full Text] [PDF]

				X. Lin, T. Okuda, J. Trang, and S. B. Howell Human REV1 Modulates the Cytotoxicity and Mutagenicity of Cisplatin in Human Ovarian Carcinoma Cells Mol. Pharmacol., May 1, 2006; 69(5): 1748 - 1754. [Abstract] [Full Text] [PDF]

				H. W. Cheung, A. C.S. Chun, Q. Wang, W. Deng, L. Hu, X.-Y. Guan, J. M. Nicholls, M.-T. Ling, Y. Chuan Wong, S. Wah Tsao, et al. Inactivation of Human MAD2B in Nasopharyngeal Carcinoma Cells Leads to Chemosensitization to DNA-Damaging Agents. Cancer Res., April 15, 2006; 66(8): 4357 - 4367. [Abstract] [Full Text] [PDF]

				X. Lin, J. Trang, T. Okuda, and S. B. Howell DNA Polymerase {zeta} Accounts for the Reduced Cytotoxicity and Enhanced Mutagenicity of Cisplatin in Human Colon Carcinoma Cells That Have Lost DNA Mismatch Repair Clin. Cancer Res., January 15, 2006; 12(2): 563 - 568. [Abstract] [Full Text] [PDF]